{"id":550657,"date":"2021-06-30T23:00:02","date_gmt":"2021-06-30T23:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=550657"},"modified":"2021-06-30T23:00:02","modified_gmt":"2021-06-30T23:00:02","slug":"myopia-market-size-and-share-analysis-leading-companies-emerging-therapies-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/myopia-market-size-and-share-analysis-leading-companies-emerging-therapies-and-epidemiology-forecast_550657.html","title":{"rendered":"Myopia Market Size and Share Analysis, Leading Companies, Emerging Therapies, and Epidemiology Forecast"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Myopia Market Size and Share Analysis, Leading Companies, Emerging Therapies, and Epidemiology Forecast\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Myopia Market Size and Share Analysis, Leading Companies, Emerging Therapies, and Epidemiology Forecast\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Myopia Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Myopia Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">According to the National Institute of Health (NIH), in the United States, myopia (also known as Nearsightedness), occurs when the eye grows too long from front to back. The eye lens starts focusing the images in front of the retina instead of focusing on the retina. Therefore, people with myopia have well near vision but poor distance vision. The distant objects appear blurry while the near ones appear normal. Undiagnosed cases may lead from headaches and strains to struggle for the clear visualization of the things in the distance.<\/p>\n<p style=\"text-align: justify;\">The signs and symptoms for myopia include squinting, feeling fatigued when driving or playing sports along with headache and strain. Myopia is associated with higher risks of glaucoma and cataract but may be protective against age-related macular degeneration and diabetic retinopathy. According to Prevent Blindness, myopia is more common in females as compared to males.<\/p>\n<p style=\"text-align: justify;\"><strong>Get FREE sample copy at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myopia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/myopia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">The <strong>Myopia Market Research Report<\/strong> covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Myopia market Size from 2017 to 2030 segmented by seven major markets.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The report provides a detailed current <strong>Myopia treatment practice\/algorithm<\/strong>, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Myopia Market \" src=\"https:\/\/www.abnewswire.com\/uploads\/dd9e2aaae44ff6a6db63da2f8974e7cf.jpg\" alt=\"Myopia Market \" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Myopia Market Key Facts<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to a study conducted by Dyanne et al., myopia occurs in 10% of the general population but is more common in older adults; the prevalence is 20% in those older than 60 years and 50% in those older than 70 years. The increased prevalence in older adults is related to peripheral vascular disease, immunologic disorders, and diabetes mellitus.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">A study by Vitale et al., in the United States, found that the prevalence of moderate myopia, defined as between &minus;2.00 D and &minus;7.9 D, nearly doubled (from 11.4% in 1971&ndash;1972 to 22.4% in 1999&ndash;2004), and that the prevalence of high myopia, which was defined as more than 8.00 D of myopia for this study, had increased eightfold during the same period (from 0.2% to 1.6%).<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">National Research Council (US) Committee on Vision states that reports from various countries and studies of various ethnic groups suggest that severe myopia has been much more common among females worldwide for at least the last century, but that the incidence of severe myopia has decreased significantly in Europe and the United States.<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key Benefits of Myopia Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Myopia market report provides an in-depth analysis of <strong>Myopia Market Size, Share, Trend, and Epidemiology Forecast<\/strong> till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report will help in developing business strategies by understanding the Myopia Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The market report covers the Myopia current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides a detailed assessment of the <strong>Myopia market<\/strong> in terms of market drivers &amp; barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Myopia Market<br \/><\/strong><strong>The Myopia market size shall increase significantly during the forecast period owing to the launch of upcoming therapies.<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted <strong>Myopia market size and share<\/strong> by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The report gives a thorough detail of the <strong>Myopia market trend<\/strong> of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.&nbsp;<\/p>\n<p style=\"text-align: justify;\"><em><strong>Request for Sample @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/myopia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Myopia&nbsp;Therapeutic Market Landscape and Key Companies<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Myopia Epidemiology<br \/><\/strong>The epidemiology section covers insights about the historical and current <strong>Myopia patient pool and forecasted trends<\/strong> for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Myopia Epidemiology Segmentation<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Total Prevalent cases of Myopia<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Gender-specific Prevalent cases of Myopia<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Age-specific prevalent cases of Myopia<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Severity-specific prevalent cases of Myopia<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Diagnosed and Treatable cases of Myopia<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Myopia Drugs Uptake and Pipeline Development Activities<br \/><\/strong>The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myopia market or expected to get launched in the market during the study period. The analysis covers <strong>Myopia market<\/strong> uptake by drugs; patient uptake by therapies; and sales of each drug.&nbsp; &nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Report&rsquo;s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.<\/p>\n<p style=\"text-align: justify;\">The report also covers the <strong>Myopia Pipeline Development Activities<\/strong> and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Myopia market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Myopia emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Currently, the market does not hold any approved product to slow the progression or treatment of Myopia. The main treatment options of single vision spectacle lenses, contact lenses, and refractive surgery do not slow the accompanying eye growth or retard the physiological changes associated with excessive axial elongation.<\/strong><\/p>\n<p style=\"text-align: justify;\">However, many novel therapies are in the late stage of development, targeting a more effective approach for the treatment of Myopia. Upcoming therapies have the potential to start a new era in their treatment if and once approved.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em><strong>Request for Sample @&nbsp;&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/myopia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">Myopia&nbsp;Novel Therapies and Emerging Technologies<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\"><strong>Myopia Companies:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Eyenovia Bio<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Sydnexis<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Nevakar<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">HOYA Corporation<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Leo Lens Pharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Santen Pharmaceutical&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many others.<\/p>\n<p style=\"text-align: justify;\"><strong>Myopia Therapies covered in the report includes:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">NVK-002<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">SYD-101<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">DE-127<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MicroPine<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And many more.<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Myopia Competitive Intelligence Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Myopia Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Myopia Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Myopia Patient Journey<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Myopia Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Myopia Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Myopia Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Key Endpoints of Myopia Treatment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Myopia Marketed Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Myopia Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Myopia Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Attribute Analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Myopia Market Outlook (7 major markets)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Myopia Access and Reimbursement Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. KOL Views on the Myopia Market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Myopia Market Drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Myopia Market Barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">*The table of contents is not exhaustive; the final content may vary.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Get FREE sample copy at:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/myopia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/myopia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Healthcare Blogs By DelveInsight<\/strong><br \/><strong>Innovative Wearable Products<\/strong><br \/>Wearables today are getting significant attention across different age groups of populations in society and also from the tech giants to capture the market share. However, just as there are two sides to a coin there are many issues and challenges associated with these devices that hampers their wide-scale adaptability. <strong>Visit to get a detailed analysis of the valuable aspects and shortcomings of the wearable devices, here: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/blog\/pros-and-cons-of-wearable-devices\/\" target=\"_blank\">Benefits and Pitfalls of the Wearable Devices&nbsp;<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><br \/>DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=myopia-market-size-and-share-analysis-leading-companies-emerging-therapies-and-epidemiology-forecast\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=myopia-market-size-and-share-analysis-leading-companies-emerging-therapies-and-epidemiology-forecast\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP DelveInsight&#8217;s &#8220;Myopia Market Insights, Epidemiology, and Market Forecast 2030&#8221; report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Myopia Market Size and Share in the United States, EU5 (Germany, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/myopia-market-size-and-share-analysis-leading-companies-emerging-therapies-and-epidemiology-forecast_550657.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[435,405,406,403,404],"tags":[],"class_list":["post-550657","post","type-post","status-publish","format-standard","hentry","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/550657","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=550657"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/550657\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=550657"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=550657"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=550657"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}